Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Early metabolic benefits of switching hydrocortisone to modified release hydrocortisone in adult adrenal insufficiency

Tools
- Tools
+ Tools

Bannon, Christopher A. M., Border, Daniel, Hanson, Petra, Hattersley, John G., Weickert, Martin O., Grossman, Ashley, Randeva, Harpal S. and Barber, Thomas M. (2021) Early metabolic benefits of switching hydrocortisone to modified release hydrocortisone in adult adrenal insufficiency. Frontiers in Endocrinology, 12 . 641247. doi:10.3389/fendo.2021.641247

[img]
Preview
PDF
Early Metabolic Benefits of WRAP-Switching-hydrocortisone-modified-release-hydrocortisone-adult-adrenal-insufficiency-2021.pdf - Published Version - Requires a PDF viewer.
Available under License Creative Commons Attribution 4.0.

Download (681Kb) | Preview
Official URL: https://doi.org/10.3389/fendo.2021.641247

Request Changes to record.

Abstract

Purpose: To compare metabolic effects of modified release hydrocortisone (MR-HC) with standard hydrocortisone (HC) therapies in adults with Adrenal Insufficiency (AI).

Methods: Adult patients (n = 12) with AI, established on HC therapy, were recruited from Endocrinology clinics at University Hospitals Coventry and Warwickshire (UHCW), UK. Baseline (HC) metabolic assessments included fasting serum HbA1C, lipid and thyroid profiles, accurate measures of body composition (BodPod), and 24-h continuous measures of energy expenditure including Sleeping Metabolic Rate (SMR) using indirect calorimetry within the Human Metabolism Research Unit, UHCW. All participants then switched HC to MR-HC with repeat (MR-HC) metabolic assessments at 3 months. Paired-sample t-tests were used for data comparisons between HC and MR-HC assessments: P-value <0.05 was considered significant.

Results: Following exclusion of 2 participants, analyses were based on 10 participants. Compared with baseline HC data, following 3 months of MR-HC therapy mean fat mass reduced significantly by −3.2 kg (95% CI: −6.0 to −0.4). Mean (SD) baseline HC fat mass vs repeat MR-HC fat mass: 31.9 kg (15.2) vs 28.7 kg (12.8) respectively, P = 0.03. Mean SMR increased significantly by +77 kcal/24 h (95% CI: 10–146). Mean (SD) baseline HC SMR vs repeat MR-HC SMR: 1,517 kcal/24 h (301) vs 1,594 kcal/24 h (344) respectively, P = 0.03. Mean body fat percentage reduced significantly by −3.4% (95% CI: −6.5 to −0.2). Other measures of body composition, energy expenditure, and biochemical analytes were equivalent between HC and MR-HC assessments.

Conclusions: In adults with AI, switching from standard HC to MR-HC associates with early metabolic benefits of reduced fat mass and increased SMR.

Item Type: Journal Article
Subjects: R Medicine > RM Therapeutics. Pharmacology
Divisions: Faculty of Medicine > Warwick Medical School > Biomedical Sciences
Faculty of Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine > Metabolic and Vascular Health (- until July 2016)
Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Adrenal glands -- Diseases, Adrenal glands -- Diseases -- Treatment, Hydrocortisone, Hydrocortisone -- Therapeutic use
Journal or Publication Title: Frontiers in Endocrinology
Publisher: Frontiers Media
ISSN: 1664-2392
Official Date: 11 March 2021
Dates:
DateEvent
11 March 2021Available
9 February 2021Accepted
Volume: 12
Article Number: 641247
DOI: 10.3389/fendo.2021.641247
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Open Access
RIOXX Funder/Project Grant:
Project/Grant IDRIOXX Funder NameFunder ID
IST-GBR-000735Takeda Pharmaceutical Companyhttp://dx.doi.org/10.13039/100008373
UNSPECIFIEDNational Institute for Health Researchhttp://dx.doi.org/10.13039/501100000272
Related URLs:
  • Publisher

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us